鲨肌醇(Scyllitol) - 药物靶点：APP_在研适应症：阿尔茨海默症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

1,3,5/2,4,6-cyclohexanehexol、Cocositol、Quercinitol

+ [5]

靶点

APP

作用机制

APP抑制剂(β-淀粉状蛋白A4抑制剂)

治疗领域

神经系统疾病

在研适应症

阿尔茨海默症

非在研适应症

攻击躁动躁郁症1型+ [1]

原研机构

Transition Therapeutics, Inc.

在研机构

Transition Therapeutics, Inc.

非在研机构

OPKO Health, Inc.Transition Therapeutics Ireland Ltd.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C6H12O6

InChIKeyCDAISMWEOUEBRE-CDRYSYESSA-N

CAS号488-59-5

关联

7

项与鲨肌醇相关的临床试验

NCT01791725 / Completed临床2期

A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

This is a prospective, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4 weeks. This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive) without dementia.

开始日期2013-09-30

申办/合作机构

OPKO Health, Inc.

[+1]

NCT01766336 / Terminated临床2期

A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.

开始日期2013-01-01

申办/合作机构

OPKO Health, Inc.

[+1]

NCT01735630 / Completed临床2期

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease

开始日期2012-11-01

申办/合作机构

OPKO Health, Inc.

[+1]

100 项与鲨肌醇相关的临床结果

登录后查看更多信息

100 项与鲨肌醇相关的转化医学

登录后查看更多信息

100 项与鲨肌醇相关的专利（医药）

登录后查看更多信息

132

项与鲨肌醇相关的文献（医药）

2024-06-01·Current Opinion in Biotechnology

Microbial synthesis of health-promoting inositols

Review

作者: Bott, Michael ; Yoshida, Ken-Ichi

D-chiro-inositol and scyllo-inositol are known for their health-promoting properties and promising as ingredients for functional foods. Strains of Bacillus subtilis and Corynebacterium glutamicum were created by metabolic engineering capable of inexpensive production of these two rare inositols from myo-inositol, which is the most common inositol in nature. In addition, further modifications have enabled the synthesis of the two rare inositols from the much-cheaper carbon sources, glucose or sucrose.

2023-11-13·Journal of Alzheimer's Disease

Quantitative Metabolomic Analysis of the Rat Hippocampus: Effects of Age and of the Development of Alzheimer’s Disease-Like Pathology

Article

作者: Telegina, Darya ; Kolosova, Nataliya ; Savina, Ekaterina ; Tsentalovich, Yuri ; Snytnikova, Olga

Background: Alzheimer’s disease (AD) is the most common type of dementia in the elderly. Incomplete knowledge about the pathogenesis of this disease determines the absence of medications for the treatment of AD today. Animal models can provide the necessary knowledge to understand the mechanisms of biochemical processes occurring in the body in health and disease. Objective: To identify the most promising metabolomic predictors and biomarkers reflecting metabolic disorders in the development of AD signs. Methods: High resolution 1H NMR spectroscopy was used for quantitative metabolomic profiling of the hippocampus of OXYS rats, an animal model of sporadic AD, which demonstrates key characteristics of this disease. Animals were examined during several key periods: 20 days group corresponds to the “preclinical” period preceding the development of AD signs, during their manifestation (3 months), and active progression (18 months). Wistar rats of the same age were used as control. Results: Ranges of variation and mean concentrations were established for 59 brain metabolites. The main metabolic patterns during aging, which are involved in energy metabolism pathways and metabolic shifts of neurotransmitters, have been established. Of particular note is the significant increase of scyllo-inositol and decrease of hypotaurine in the hippocampus of OXYS rats as compared to Wistars for all studied age groups. Conclusions: We suggest that the accumulation of scyllo-inositol and the reduction of hypotaurine in the brain, even at an early age, can be considered as predictors and potential biomarkers of the development of AD signs in OXYS rats and, probably, in humans.

2023-04-20·Molecules (Basel, Switzerland)

Myo-Inositol, Scyllo-Inositol, and Other Minor Carbohydrates as Authenticity Markers for the Control of Italian Bulk, Concentrate, and Rectified Grape Must

Article

作者: Larcher, Roberto ; Paolini, Mauro ; Tonidandel, Loris ; Perini, Matteo ; Allari, Letizia ; Guardini, Katia ; Finato, Fabio

Myo-inositol polyalc. is a characteristic component of natural and concentrated grape musts (CMs), and Regulation (EU) number 1308/2013 prescribes its presence as a marker of the authenticity of rectified concentrated must (RCM).Other polyalcs. besides myo-inositol, such as scyllo-inositol or minor sugars, could be considered authenticity markers, but an extensive search in the literature yielded no exhaustively investigated study of their concentration variability in genuine products.The aim of this study was to create an extensive national data bank of minor carbohydrates profiles and investigate the impact of the geog. origin and the different vintages on the concentration of these compounds; to this end, 450 authentic Italian grape musts of different varieties were sampled and analyzed during the harvest season in 2019, 2020, and 2021.The grape musts from the Italian wine-growing areas CII and CIIIb had myo- and scyllo-inositol contents always higher than 756 and 39 mg/kg of sugar, resp.Conversely, also considering other mono- and disaccharides, sucrose, sorbitol, lactose, maltose, and isomaltose showed contents always lower than 534, 1207, 390, 2222, and 1639 mg/kg of sugar, resp.The general applicability to the CM and RCM of the proposed authenticity thresholds, established in the must, was demonstrated by studying the influence of must concentration on the myo- and scyllo-inositol content.Inter-laboratory comparison experiments were also conducted to harmonize and characterize laboratory methods and validate the anal. dataset.Based on the obtained results, the text of the EU legislation (Reg. (EU) 1308/2013), which defines the characteristics of the must and the CRM product, should be revised.

100 项与鲨肌醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	鲨肌醇	-	DB03106

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床3期	-	Transition Therapeutics, Inc.	-
阿尔茨海默症	临床3期	加拿大	Transition Therapeutics Ireland Ltd.	-
阿尔茨海默症	临床3期	美国	Transition Therapeutics Ireland Ltd.	-
躁郁症1型	临床2期	捷克	OPKO Health, Inc.	2012-08-31
躁郁症1型	临床2期	罗马尼亚	OPKO Health, Inc.	2012-08-31
躁郁症1型	临床2期	土耳其	OPKO Health, Inc.	2012-08-31
躁郁症1型	临床2期	美国	OPKO Health, Inc.	2012-08-31
躁郁症1型	临床2期	立陶宛	OPKO Health, Inc.	2012-08-31
阿尔茨海默症	临床1期	西班牙	Transition Therapeutics Ireland Ltd.	-
阿尔茨海默症	临床1期	英国	Transition Therapeutics Ireland Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAIC2011	N/A	阿尔茨海默症	353	ELND005 250mg	選鑰憲憲廠鏇憲鏇餘襯(窪鹽廠憲觸製鏇鹹鏇艱) = 遞網衊觸積願艱壓糧餘築簾齋鬱餘築遞簾廠鹽 (糧選淵鹽製鑰鑰鹹衊夢 )	-	2011-07-01
NCT01791725 (CTgov)	临床2期	痴呆 \| 唐氏综合征	23	ELND005 (ELND005 BID)	(窪廠製艱壓鬱顧顧獵鬱) = 顧膚範遞願簾構鏇鬱鏇鹽願鏇鹽築衊鏇蓋艱鹽 (壓鹹餘膚簾繭選製鹽製, 襯積艱廠齋蓋淵衊獵襯 ~ 襯選廠獵觸鏇顧獵簾鹹) 更多	-	2016-01-29
				ELND005 (ELND005 QD)	(窪廠製艱壓鬱顧顧獵鬱) = 遞廠觸夢鹹廠簾糧觸鏇鹽願鏇鹽築衊鏇蓋艱鹽 (壓鹹餘膚簾繭選製鹽製, 廠製衊蓋窪夢選鹽鬱廠 ~ 齋鏇製壓廠觸艱壓鹽願) 更多
NCT01766336 (CTgov)	临床2期	阿尔茨海默症 \| 攻击 \| 躁动	296	ELND005 (ELND005/ELND005)	(繭廠蓋淵蓋鬱築築鹹艱) = 衊糧鬱鹹衊積構選糧顧醖鬱選齋獵願醖夢廠顧 (遞願齋鏇網獵齋築艱遞, 衊築襯壓夢製築鏇鏇範 ~ 鹽壓積願廠構壓繭積顧) 更多	-	2016-05-13
				Placebo+ELND005 (Placebo/ELND005)	(繭廠蓋淵蓋鬱築築鹹艱) = 醖壓淵繭觸網淵壓築製醖鬱選齋獵願醖夢廠顧 (遞願齋鏇網獵齋築艱遞, 網餘顧繭構築獵醖窪積 ~ 淵淵簾鏇顧範鏇夢齋顧) 更多
NCT01735630 (CTgov)	临床2期	阿尔茨海默症 \| 攻击 \| 躁动	350	ELND005 (ELND005)	觸積蓋襯窪鬱築蓋製襯(壓製壓艱選範鏇醖蓋繭) = 製壓鹹繭醖淵夢遞範壓選鏇積網糧願獵鏇鹽築 (窪憲壓鏇鑰醖餘壓醖願, 製選簾襯糧淵鏇餘鏇鑰 ~ 襯膚夢糧選鑰選網膚鏇) 更多	-	2016-08-15
				placebo (Placebo)	觸積蓋襯窪鬱築蓋製襯(壓製壓艱選範鏇醖蓋繭) = 襯醖鏇簾廠顧餘齋築夢選鏇積網糧願獵鏇鹽築 (窪憲壓鏇鑰醖餘壓醖願, 糧鬱膚衊繭壓網網鏇選 ~ 鏇獵鹹獵觸製糧鹽選蓋) 更多
AD201 (AAIC2012)	N/A	阿尔茨海默症	351	ELND005 (Scyllo-inositol) 250mg	蓋製範餘鹽膚觸範構醖(網鹹壓鏇積蓋窪壓繭鏇) = 膚膚艱繭淵鏇糧鏇衊壓繭衊範膚範觸鹽製夢鑰 (鏇醖憲壓夢憲築鑰遞鏇, -36% ~ -45%)	-	2012-07-01
				ELND005 (Scyllo-inositol) 1000mg	蓋製範餘鹽膚觸範構醖(網鹹壓鏇積蓋窪壓繭鏇) = 襯夢蓋遞繭製獵衊繭繭繭衊範膚範觸鹽製夢鑰 (鏇醖憲壓夢憲築鑰遞鏇, -61% ~ -64%)
NCT00568776 (CTgov)	临床2期	阿尔茨海默症	353	Placebo (Placebo BID)	鬱衊夢鹹憲築餘餘鹹憲(簾廠襯築簾築獵憲選繭) = 遞鹽鑰壓膚觸夢顧簾廠壓襯醖築鹽獵鏇網簾膚 (蓋襯衊顧膚鹹獵餘觸觸, 範廠艱醖簾願鏇獵積膚 ~ 糧積艱網糧齋襯製築醖) 更多	-	2012-03-29
				ELND005 (ELND005 250 mg BID)	鬱衊夢鹹憲築餘餘鹹憲(簾廠襯築簾築獵憲選繭) = 鑰簾繭壓襯餘構網繭鏇壓襯醖築鹽獵鏇網簾膚 (蓋襯衊顧膚鹹獵餘觸觸, 膚構網構鹹膚糧遞觸淵 ~ 鹹餘顧願壓鹹壓積觸觸) 更多
NCT00934050 (CTgov)	临床2期	阿尔茨海默症	103	Placebo+ELND005 (Placebo/ELND005 250mg BID)	(糧構餘築襯積夢壓鹽夢) = 簾觸鬱構簾範夢窪願憲鹹齋網壓網鏇蓋壓窪簾 (網膚鬱衊鹽餘築願壓鑰, 襯觸醖觸壓範襯範壓膚 ~ 觸鏇觸網製遞廠壓構醖) 更多	-	2015-05-13
				ELND005 (250 mg/ELND005 250 mg BID)	(糧構餘築襯積夢壓鹽夢) = 觸醖鑰顧簾廠壓簾觸製鹹齋網壓網鏇蓋壓窪簾 (網膚鬱衊鹽餘築願壓鑰, 選獵衊願鏇艱糧憲築願 ~ 積夢繭餘壓觸構鹽餘願) 更多
AAIC2009	N/A	淀粉样蛋白斑	-	ELND005 (scylloinositol)	淵範窪鹽憲網餘繭餘憲(鏇獵醖顧鏇醖夢獵衊繭) = 廠獵選憲廠範膚鬱遞獵築繭觸顧蓋廠壓願顧鹽 (鬱齋鑰夢築廠鏇鑰積鏇 )	-	2009-07-01